Losortan Potassium
Product Images NDC 45865-684

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 45865-684). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (684 49)

Losartan Potassium Tablets 50 mg, generic for Cozaar, in a package containing 100 tablets. The label includes dosage strength, generic status, and manufacturer information from Zydus Pharmaceuticals USA Inc. It also provides warnings about pregnancy, dizziness, and alcohol use, with instructions to take the tablets daily or as directed by a physician. The label includes both English and Spanish text and instructions to peel for more information.*

FDA Label Image

Figure1 (Figure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dashed line) and Losartan Potassium (solid line). The graph shows a slower increase in events with Losartan Potassium, indicating a 13% adjusted risk reduction with a statistical significance of p=0.021.*

FDA Label Image

Figure2 (Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for two drugs: Losartan Potassium (solid line) and Atenolol (dashed line). The graph depicts increasing stroke percentages over time, with Losartan Potassium showing a lower percentage compared to Atenolol. An annotation notes a 25% adjusted risk reduction with a p-value of 0.001.*

FDA Label Image

Figure3 (Figure3)

A forest plot comparing event rates and hazard ratios for Losartan Potassium versus Atenolol in a clinical study. The chart displays results for primary composite outcomes and stroke (fatal/non-fatal) across patient subgroups by age, gender, race, isolated systolic hypertension status, diabetes, and cardiovascular disease history. Hazard ratios with 95% confidence intervals are graphically shown to indicate favorability toward Losartan Potassium or Atenolol.*

FDA Label Image

Figure4 (Figure4)

A line graph comparing the percentage of patients with an event over a 48-month period between Losartan Potassium Tablet and Placebo groups. The graph shows a 16.1% risk reduction with Losartan Potassium, with statistical significance indicated (p=0.022). The x-axis represents months, and the y-axis represents the percentage of patients with an event.*

FDA Label Image

Structure (Structure)

Chemical structure of Losortan Potassium, showing the molecular arrangement of atoms including chlorine, nitrogen, potassium ion, and organic components typical of the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.